Australia markets open in 3 hours 26 minutes

EQRx, Inc. (EQRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.7600+0.2600 (+5.78%)
At close: 04:00PM EDT
4.7600 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.5000
Open4.3800
Bid3.0000 x 900
Ask6.0000 x 1000
Day's range4.3800 - 4.8600
52-week range2.6300 - 11.1000
Volume1,217,390
Avg. volume1,428,923
Market cap2.321B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.3090
Earnings date13 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.60
  • GlobeNewswire

    EQRx Reports First Quarter 2022 Financial Results and Recent Corporate Progress

    New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3 GEMSTONE-302 study of sugemalimab plus chemotherapy in first-line Stage IV NSCLCContinue to expect first regulatory submissions for aumolertinib and sugemalimab ex-U.S. in 2H 2022; constructive conversations with the FDA are ongoing to gain greater clarity on the regulatory path forward in the U.S.Continue to

  • GlobeNewswire

    EQRx to Hold First Quarter 2022 Financial Results Conference Call on Friday, May 13, 2022

    CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced it will host a conference call and webcast on Friday, May 13, 2022 at 8:00 a.m. ET to report its first quarter 2022 financial results and provide a business update. A live webcast can be accessed by visiting the Investors section of the Company’s website at investors.

  • GlobeNewswire

    EQRx Announces New Data on Lead Oncology Programs to Be Presented at 2022 ASCO Annual Meeting

    First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung cancer (NSCLC)Oral presentation featuring the primary analysis from Phase 2 GEMSTONE-201 study of sugemalimab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (ENKTL), a rare and aggressive form of Non-Hodgkin lymphomaInitial presentation on the activity of aumolertinib in patient